Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC
Authors
Loading...
Phase I/II trial evaluates EP0031’s effectiveness in advanced RET-fusion-positive NSCLC, suggesting a potential combined treatment approach.
Rubio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: